Histogen (NASDAQ:HSTO) completed patient enrollment in its Phase 1b/2a clinical trial evaluating HST 001 for the treatment of androgenic alopecia in men.
The trial enrolled 36 subjects with male pattern hair loss who will receive 20 injections, divided between the temporal recession and vertex scalp areas, at each of week zero, six and 12.
“We are pleased to have accomplished this clinical milestone with HST 001 and we look forward to completing the treatment phase of the study and releasing topline data in the fourth quarter of this year,” Richard Pascoe, Histogen’s president and CEO, said in a statement.
“The on-time achievement of this milestone demonstrates our ability to execute on the clinical development plans for HST 001, which has the potential to stimulate new long-lasting hair growth in contrast to existing therapies that focus on reducing hair loss,” he added.
